The recent JASN article by Binois et al.1 offers important insights into the prognostic value of kidney histopathology in scleroderma renal crisis. Through histologic clustering and outcome analysis, the study highlights marked heterogeneity and identifies acute arteriolar thrombotic microangiopathy and onion skinning as predictors of kidney failure.1 Interestingly, chronic changes such as glomerulosclerosis and interstitial fibrosis were linked to better preserved kidney function, suggesting a potential adaptive or protective role. A key area of ongoing uncertainty concerns the role of angiotensin-converting enzyme (ACE) inhibitors when administered before the onset of scleroderma renal crisis. Although ACE inhibitors are well established as a cornerstone of management of scleroderma renal crisis due to their proven efficacy in controlling malignant hypertension and limiting further vascular injury, their prophylactic use in patients with systemic sclerosis remains a matter of substantial controversy. Several observational studies have paradoxically linked prior ACE inhibitor use to a higher risk of scleroderma renal crisis.2,3 However, a critical limitation of these studies lies in the lack of accompanying kidney histopathologic data, which impedes a mechanistic interpretation of this apparent contradiction. This study offers a valuable opportunity to address a critical gap in our understanding of the effect of prior ACE inhibitor use in scleroderma renal crisis. Notably, approximately 30% of patients in the cohort had been treated with ACE inhibitors before the onset of scleroderma renal crisis. This observation prompts several important considerations, including the possibility that prior exposure to ACE inhibitors may have been associated with less severe acute histologic lesions.4 A focused subgroup analysis comparing histopathologic features and kidney outcomes between patients with and without prior ACE inhibitor use could provide meaningful insights. Such data may help determine whether ACE inhibitors exert a protective or deleterious effect when administered prophylactically in patients with systemic sclerosis. The apparent discrepancy between the established therapeutic efficacy of ACE inhibitors in the treatment of scleroderma renal crisis and their potentially adverse effects when used prophylactically remains insufficiently understood from a pathophysiologic perspective. To clarify this issue, future studies should investigate the interactions between ACE inhibitors and the progressive vascular injury that characterizes systemic sclerosis. This will require the integration of clinical, hemodynamic, and immunologic data, including complement activation, as well as histopathologic findings to achieve a more comprehensive understanding of pathogenesis of scleroderma renal crisis.
Read more